Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

Science Translational Medicine

Volumn 9, Issue 393, 2017, Pages

  Nolan, Emma ^a,b   Savas, Peter ^b,c   Policheni, Antonia N ^a,b   Darcy, Phillip K ^b,c   Vaillant, François ^a,b   Mintoff, Christopher P ^c   Dushyanthen, Sathana ^b,c   Mansour, Mariam ^b,c   Pang, Jia Min B ^b,c   Fox, Stephen B ^b,c   Perou, Charles M ^d,e   Visvader, Jane E ^a,b   Gray, Daniel H D ^a,b   Loi, Sherene ^b,c   Lindeman, Geoffrey J ^a,b,f  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Parkville Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HERMES ANTIGEN; HLA ANTIGEN; INDUCIBLE T CELL COSTIMULATOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUROPILIN 1; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA1 PROTEIN, MOUSE; CD274 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; CTLA4 GENE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PDCD1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MUTATION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 85020391358     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aal4922     Document Type: Article

References (44)

1. W. D. Foulkes, I. E. Smith, J. S. Reis-Filho, Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010).
2. C. J. Lord, A. Ashworth, BRCAness revisited. Nat. Rev. Cancer 16, 110-120 (2016).
3. P. Bouwman, J. Jonkers, Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 20, 540-547 (2014).
4. R. D. Schreiber, L. J. Old, M. J. Smyth, Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
5. S. L. Topalian, C. G. Drake, D. M. Pardoll, Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
6. E. I. Buchbinder, A. Desai, CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98-106 (2016).
7. F. S. Hodi, S. J. ODay, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. M. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
8. M. Reck, D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer; KEYNOTE-024 Investigators, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823-1833 (2016).
9. G. Bianchini, J. M. Balko, I. A. Mayer, M. E. Sanders, L. Gianni, Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674-690 (2016).
10. R. Nanda, L. Q. M. Chow, E. C. Dees, R. Berger, S. Gupta, R. Geva, L. Pusztai, K. Pathiraja, G. Aktan, J. D. Cheng, V. Karantza, L. Buisseret, Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460-2467 (2016).
11. I. Melero, D. M. Berman, M. A. Aznar, A. J. Korman, J. L. P. Gracia, J. Haanen, Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
12. R. M. Chabanon, M. Pedrero, C. Lefebvre, A. Marabelle, J.-C. Soria, S. Postel-Vinay, Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res. 22, 4309-4321 (2016).
13. S. R. Lakhani, J. Jacquemier, J. P. Sloane, B. A. Gusterson, T. J. Anderson, M. J. van de Vijver, L. M. Farid, D. Venter, A. Antoniou, A. Storfer-Isser, E. Smyth, C. M. Steel, N. Haites, R. J. Scott, D. Goldgar, S. Neuhausen, P. A. Daly, W. Ormiston, R. McManus, S. Scherneck, B. A. Ponder, D. Ford, J. Peto, D. Stoppa-Lyonnet, Y.-J. Bignon, J. P. Struewing, N. K. Spurr, D. T. Bishop, J. G. M. Klijn, P. Devilee, C. J. Cornelisse, C. Lasset, G. Lenoir, R. B. Barkardottir, V. Egilsson, U. Hamann, J. Chang-Claude, H. Sobol, B. Weber, M. R. Stratton, D. F. Easton, Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90, 1138-1145 (1998).
14. P. Savas, R. Salgado, C. Denkert, C. Sotiriou, P. K. Darcy, M. J. Smyth, S. Loi, Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228-241 (2016).
15. C. Denkert, G. von Minckwitz, J. C. Brase, B. V. Sinn, S. Gade, R. Kronenwett, B. M. Pfitzner, C. Salat, S. Loi, W. D. Schmitt, C. Schem, K. Fisch, S. Darb-Esfahani, K. Mehta, C. Sotiriou, S. Wienert, P. Klare, F. André, F. Klauschen, J.-U. Blohmer, K. Krappmann, M. Schmidt, H. Tesch, S. Kummel, P. Sinn, C. Jackisch, M. Dietel, T. Reimer, M. Untch, S. Loibl, Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 33, 983-991 (2015).
16. S. Luen, B. Virassamy, P. Savas, R. Salgado, S. Loi, The genomic landscape of breast cancer and its interaction with host immunity. Breast 29, 241-250 (2016).
17. R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Van den Eynden, F. L. Baehner, F. Penault-Llorca, E. A. Perez, E. A. Thompson, W. F. Symmans, A. L. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. L. Rimm, K. H. Allison, J. S. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259-271 (2015).
18. X. Xu, K.-U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris, C.-X. Deng, Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22, 37-43 (1999).
19. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin, G. R. Bignell, N. Bolli, A. Borg, A.-L. Børresen-Dale, S. Boyault, B. Burkhardt, A. P. Butler, C. Caldas, H. R. Davies, C. Desmedt, R. Eils, J. E. Eyfjörd, J. A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. Jäger, D. T. W. Jones, D. Jones, S. Knappskog, M. Kool, S. R. Lakhani, C. López-Otín, S. Martin, N. C. Munshi, H. Nakamura, P. A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X. S. Puente, K. Raine, M. Ramakrishna, A. L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. N. Schumacher, P. N. Span, J. W. Teague, Y. Totoki, A. N. J. Tutt, R. Valdés-Mas, M. M. van Buuren, L. van 't Veer, A. Vincent-Salomon, N. Waddell, L. R. Yates; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, J. Zucman-Rossi, P. A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. M. Grimmond, R. Siebert, E. Campo, T. Shibata, S. M. Pfister, P. J. Campbell, M. R. Stratton, Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
20. S. Rottenberg, A. O. H. Nygren, M. Pajic, F. W. B. van Leeuwen, I. van der Heijden, K. van de Wetering, X. Liu, K. E. de Visser, K. G. Gilhuijs, O. van Tellingen, J. P. Schouten, J. Jonkers, P. Borst, Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 12117-12122 (2007).
21. L. Zitvogel, L. Apetoh, F. Ghiringhelli, G. Kroemer, Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008).
22. L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer, Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97-111 (2017).
23. S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin, B. Chauffert, P. Fumoleau, F. Ghiringhelli, Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res. 14, 2413-2420 (2008).
24. M. E. Keir, M. J. Butte, G. J. Freeman, A. H. Sharpe, PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
25. N. Malandro, S. Budhu, N. F. Kuhn, C. Liu, J. T. Murphy, C. Cortez, H. Zhong, X. Yang, G. Rizzuto, G. Altan-Bonnet, T. Merghoub, J. D. Wolchok, Clonal abundance of tumor-specific CD4+ T cells potentiates efficacy and alters susceptibility to exhaustion. Immunity 44, 179-193 (2016).
26. C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G. N. Hortobagyi, L. Pusztai, Response to neoadjuvant therapy and long-Term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
27. L. A. Emens, F. S. Braiteh, P. Cassier, J.-P. DeLord, J. P. Eder, X. Shen, Y. Xiao, Y. Wang, P. S. Hegde, D. S. Chen, Abstract PD1-6: Inhibition of PD-L1 by mpdl3280a leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res. 75, 1-6 (2015).
28. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, C. L. Cowey, C. D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. F. Ferrucci, A. Hill, J. Wagstaff, M. S. Carlino, J. B. Haanen, M. Maio, I. Marquez-Rodas, G. A. McArthur, P. A. Ascierto, G. V. Long, M. K. Callahan, M. A. Postow, K. Grossmann, M. Sznol, B. Dreno, L. Bastholt, A. Yang, L. M. Rollin, C. Horak, F. S. Hodi, J. D. Wolchok, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
29. S. Antonia, S. B. Goldberg, A. Balmanoukian, J. E. Chaft, R. E. Sanborn, A. Gupta, R. Narwal, K. Steele, Y. Gu, J. J. Karakunnel, N. A. Rizvi, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol. 17, 299-308 (2016).
30. H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis, L. Chen, Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
31. K. C. Strickland, B. E. Howitt, S. A. Shukla, S. Rodig, L. L. Ritterhouse, J. F. Liu, J. E. Garber, D. Chowdhury, C. J. Wu, A. D. D'Andrea, U. A. Matulonis, P. A. Konstantinopoulos, Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587-13598 (2016).
32. Y. Schwitalle, M. Kloor, S. Eiermann, M. Linnebacher, P. Kienle, H. P. Knaebel, M. Tariverdian, A. Benner, M. von Knebel Doeberitz, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134, 988-997 (2008).
33. H. Westdorp, F. L. Fennemann, R. D. A. Weren, T. M. Bisseling, M. J. L. Ligtenberg, C. G. Figdor, G. Schreibelt, N. Hoogerbrugge, F. Wimmers, I. J. de Vries, Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol. Immunother. 65, 1249-1259 (2016).
34. T. N. Schumacher, R. D. Schreiber, Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
35. B. Li, C. N. Dewey, RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
36. H. Wickham, ggplot2: Elegant Graphics for Data Analysis (Springer, 2009).
37. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
38. Z. Lai, A. Markovets, M. Ahdesmaki, B. Chapman, O. Hofmann, R. McEwen, J. Johnson, B. Dougherty, J. C. Barrett, J. R. Dry, VarDict: A novel and versatile variant caller for nextgeneration sequencing in cancer research. Nucleic Acids Res. 44, e108 (2016).
39. X. Jian, E. Boerwinkle, X. Liu, In silico prediction of splice-Altering single nucleotide variants in the human genome. Nucleic Acids Res. 42, 13534-13544 (2014).
40. T. M. Keane, L. Goodstadt, P. Danecek, M. A. White, K. Wong, B. Yalcin, A. Heger, A. Agam, G. Slater, M. Goodson, N. A. Furlotte, E. Eskin, C. Nellåker, H. Whitley, J. Cleak, D. Janowitz, P. Hernandez-Pliego, A. Edwards, T. G. Belgard, P. L. Oliver, R. E. McIntyre, A. Bhomra, J. Nicod, X. Gan, W. Yuan, L. van der Weyden, C. A. Steward, S. Bala, J. Stalker, R. Mott, R. Durbin, I. J. Jackson, A. Czechanski, J. A. Guerra-Assunção, L. R. Donahue, L. G. Reinholdt, B. A. Payseur, C. P. Ponting, E. Birney, J. Flint, D. J. Adams, Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289-294 (2011).
41. R. Rosenthal, N. McGranahan, J. Herrero, B. S. Taylor, C. Swanton, Deconstructsigs: Delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
42. E. C. Stack, C. Wang, K. A. Roman, C. C. Hoyt, Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46-58 (2014).
43. E. Nolan, F. Vaillant, D. Branstetter, B. Pal, G. Giner, L. Whitehead, S. W. Lok, G. B. Mann; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), K. Rohrbach, L.-Y. Huang, R. Soriano, G. K. Smyth, W. C. Dougall, J. E. Visvader, G. J. Lindeman, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat. Med. 22, 933-939 (2016).
44. M. I. Harrell, B. M. Iritani, A. Ruddell, Lymph node mapping in the mouse. J. Immunol. Methods 332, 170-174 (2008).